Abstract: The invention concerns a method for detecting indicators for determining diseases (disease indicators), in which aggregates of misfolded proteins play a role, and a method for selective quantitation and/or characterization of these disease indicators.

Abstract: The invention relates to a method for in vitro diagnosis of the presence of a mental disorder in a human individual or the predisposition of the human individual to the mental disorder, wherein the mental disorder is associated with a dysfunctional DISC1 protein pathway or disturbed dopamine homeostasis, the method comprising: a) measuring in a sample of a body tissue or fluid from the individual the expression levels of at least two marker genes, each of which coding for at least one marker protein; b) comparing the measured expression levels to predetermined threshold values representing the expression levels of said marker genes in a healthy population; and c) based on the comparison, determining whether the individual has the mental disorder or a predisposition to the mental disorder, wherein the measured expression levels are indicative to the mental disorder or disposition if the measured expression levels of said marker genes exceed, reach or fall below the predetermined threshold value.

Abstract: The invention concerns a method for detecting indicators for determining diseases (disease indicators), in which aggregates of misfolded proteins play a role, and a method for selective quantitation and/or characterization of these disease indicators.

Abstract: A composition includes D-peptides or antibodies to at least one of to prevent a disease and to treat the disease, wherein the D-peptides interact with an amyloid peptide and the antibodies bind to both the D-peptide and the amyloid peptide.

Abstract: The invention relates to an antibody, antibody fragment or derivative thereof which specifically recognizes a prion protein and which comprises a complementarity determining region (CDR), a retro-inverso D-peptide of said CDR and/or an anti-idiotypic antibody, antibody fragment or derivative thereof which recognizes said CDR. The invention further concerns a nucleic acid molecule encoding said antibody, antibody fragment or derivative thereof as well as a method for generating an antibody, antibody fragment or derivative thereof that specifically recognizes a prion protein, wherein an antibody that recognizes a specific domain of the prion protein is generated, an antigen-specific amino acid sequence is isolated from said antibody, and an anti-idiotypic antibody, antibody fragment or derivative thereof, which recognizes said antigen-specific amino acid sequence, is generated.

Abstract: The invention relates to an antibody, antibody fragment or derivative thereof which specifically recognizes a prion protein and which comprises a complementarity determining region (CDR), a retro-inverso D-peptide of said CDR and/or an anti-idiotypic antibody, antibody fragment or derivative thereof which recognizes said CDR. The invention further concerns a nucleic acid molecule encoding said antibody, antibody fragment or derivative thereof as well as a method for generating an antibody, antibody fragment or derivative thereof that specifically recognizes a prion protein, wherein an antibody that recognizes a specific domain of the prion protein is generated, an antigen-specific amino acid sequence is isolated from said antibody, and an anti-idiotypic antibody, antibody fragment or derivative thereof, which recognizes said antigen-specific amino acid sequence, is generated.

Abstract: The present invention relates to a composition comprising D-peptides or antibodies for use as a therapeutic and/or for disease prevention, wherein a) the D-peptides interact with an amyloid peptide and b) the antibodies bind to the D-peptide from a) and additionally to the amyloid peptide from a).

Abstract: The invention relates to compounds according to general formula (1) and/or their enantiomers, diastereomers as well as their pharmaceutically compatible salts, and to the use thereof for producing a medicament suited for treating diseases associated with misfolded proteins.

Abstract: The invention relates to an antibody, antibody fragment or derivative thereof which specifically recognizes a prion protein and which comprises a complementarity determining region (CDR), a retro-inverso D-peptide of said CDR and/or an anti-idiotypic antibody, antibody fragment or derivative thereof which recognizes said CDR. The invention further concerns a nucleic acid molecule encoding said antibody, antibody fragment or derivative thereof as well as a method for generating an antibody, antibody fragment or derivative thereof that specifically recognizes a prion protein, wherein an antibody that recognizes a specific domain of the prion protein is generated, an antigen-specific amino acid sequence is isolated from said antibody, and an anti-idiotypic antibody, antibody fragment or derivative thereof, which recognizes said antigen-specific amino acid sequence, is generated.

Abstract: Methods of preparing monoclonal antibodies that differentially bind to a single conformer of a protein of interest are described. Passive immunization using these antibodies as well as use of conformer-specific antibodies as diagnostic reagents for the purpose of stratification of patient populations with regards to disease outcome, drug efficacy or drug sensitivity is also disclosed as well as active immunization with the protein conformer. In the screening techniques, detection can be for example by tissue immunostaining, western blotting or solution IP. A specific mab termed 7VC which shows conformation specificity to CtmPrP, a prion protein conformer that triggers neurodegeneration under specific assay conditions of pH and copper concentration, is described. A second specific antibody termed 19B10 shows conformation specificity for NtmPrP, a prion protein conformer that downregulates total PrP expression and effects cell differentiation.

Abstract: An antibody for diagnosis or treatment of neuropsychiatric diseases, in particular schizophrenia, depression or bipolar affective disorders, is characterized in that the antibody recognizes misfolded specific proteins that can be assigned to one of the diseases, and a method for diagnosis by means of antibodies that bind to neuropsychiatric disease-specific proteins.

Abstract: The invention relates to the use of special conformers of the DISC1 protein as a marker or target for chronic psychiatric illnesses, particularly schizophrenia, bipolar disorder, or depression.

Abstract: The invention relates to compounds according to general formula (1) and/or their enantiomers, diastereomers, and their pharmaceutically compatible salts, and their use to manufacture a medication as well as medications. The compounds are suited for treatment of diseases connected with misfolded proteins.

Abstract: The invention relates to compounds according to general formula (1) and/or their enantiomers, diastereomers as well as their pharmaceutically compatible salts, and to the use thereof for producing a medicament suited for treating diseases associated with misfolded proteins.

Abstract: An antibody for diagnosis or treatment of neuropsychiatric diseases, in particular schizophrenia, depression or bipolar affective disorders, is characterized in that the antibody recognizes misfolded specific proteins that can be assigned to one of the diseases, and a method for diagnosis by means of antibodies that bind to neuropsychiatric disease-specific proteins.

Abstract: Methods of preparing monoclonal antibodies that differentially bind to a single conformer of a protein of interest are described. Passive immunization using these antibodies as well as use of conformer-specific antibodies as diagnostic reagents for the purpose of stratification of patient populations with regards to disease outcome, drug efficacy or drug sensitivity is also disclosed as well as active immunization with the protein conformer. In the screening techniques, detection can be for example by tissue immunostaining, western blotting or solution IP. A specific mab termed 7VC which shows conformation specificity to CtmPrP, a prion protein conformer that triggers neurodegeneration under specific assay conditions of pH and copper concentration, is described. A second specific antibody termed 19B10 shows conformation specificity for NtmPrP, a prion protein conformer that downregulates total PrP expression and effects cell differentiation.

Abstract: The presented invention relates to monoclonal antibodies useful in sensitive and specific immunological assays for the identification of prions in various tissues and body fluids, the production of such monoclonal antibodies by means of immunization of PrP0/0 mice by means of a new recombinant fragment of PrP and the use of the antibodies, e.g. for therapeutic and preventive treatments of humans and animals suffering from prion diseases.

Abstract: A number of polypeptides exist in different three-dimensional conformations, or “conformers,” which have different biological functions despite having the same or substantially the same primary polypeptide sequences. The existence of different polypeptide conformers underlies to a variety of disease states, which may be assessed using antibody that is specific for a given conformer. Thus, such antibody thus is useful for identifying or detecting certain conformers within a mixed population of conformers.

Abstract: The invention relates to an agent and/or pharmaceutical active ingredient and to a method for the treatment, prevention and diagnosis of TSE, and to a method for the production of an agent and/or pharmaceutical active ingredient. According to the invention, peptides and/or nucleotide sequences coding for said peptides are provided as disclosed in the sequence protocols 127 and partial sequences thereof are disclosed. Treatment or prevention of the TSE disease, for example, in humans with Jacob Creutzfeldt syndrome, kuru, Gertmann Sträussler-Scheinker syndrome and FFI (fatal familial insomnia) can be carried out with the aid of the inventive peptides. TSE diseases are also known in animals, such as Scrapie in sheep, BSE in cows and CWD in wild animals.

Abstract: The presented invention relates to monoclonal antibodies useful in sensitive and specific immunological assays for the identification of prions in various tissues and body fluids, the production of such monoclonal antibodies by means of immunization of PrP0/0 mice by means of a new recombinant fragment of PrP and the use of the antibodies, e.g. for therapeutic and preventive treatments of humans and animals suffering from prion diseases.